Medical Company News

Genzyme says Unsolicited Proposal, not right time to sell the company

Genzyme responding to Sanofi-aventis $18.5 billion All-Cash Offer says that “without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic takeover proposal does not begin to recognize the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline.” [...]



Sanofi-aventis $18.5 billion All-Cash Offer for Genzyme

Sanofi-aventis announced non-binding proposal to acquire Genzyme in an all-cash transaction valued at approximately $18.5 billion. Sanofi-aventis is offering $69 per Genzyme share in cash, representing a 38% premium over Genzyme’s unaffected share price of $49.86 on July 1, 2010. Sanofi-aventis’ offer also represents a premium of almost 31% over the one-month historical average share [...]



Get Adobe Flash playerPlugin by wpburn.com wordpress themes